+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy



Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy



Clinical Advances in Hematology and Oncology 6(12): 1-15



Myelodysplastic syndrome (MDS) is relatively common, with an incidence estimated as high as 50 cases per 100,000 people per year. This cancer mainly affects older (>or=60 years) patients. MDS refers to a collection of hematologic malignancies that share an ineffective production, or hematopoiesis, of normal bone marrow or myeloid cells. As progressive bone marrow failure occurs, patients generally display gradually worsening cytopenias specific to the type of bone marrow cell affected, such as thrombocytopenia or neutropenia. MDS patients often develop disease-related anemia requiring chronic blood transfusion; this can lead to complications including iron overload. As MDS progresses and the number of bone marrow blasts increases, the disease transforms into acute myelogenous leukemia (AML). Several classification systems have been developed to identify and differentiate particular types of MDS. Proper identification is essential, allowing the oncologist to determine prognosis, as well as the optimal therapeutic strategy. Several agents have been developed or are under investigation for the treatment of MDS, with the therapeutic goal of increasing survival and decreasing the rate of AML transformation. Currently, 3 agents are FDA-approved: azacitidine, decitabine, and lenalidomide. This clinical roundtable will discuss the optimal management of patients with each of these approved therapies, as well as the various classification systems used to differentiate MDS subtypes for treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 055398041

Download citation: RISBibTeXText

PMID: 19385003


Related references

Advances in the management of low- to intermediate-risk myelodysplastic syndrome: Integrating the National Comprehensive Cancer Network guidelines. Clinical Journal of Oncology Nursing 10(2): 197-208, 2006

How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments. 2013

How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments. Current Pharmaceutical Design 19(30): 5362-5373, 2014

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116(17): 3163-3170, 2010

Recent advances in therapy of myelodysplastic syndromes. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20(6): 1522-1525, 2013

Recent Research Advances on Pediatric Myelodysplastic Syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 23(3): 898-902, 2015

Recent advances in the classification and treatment of myelodysplastic syndrome. Orvosi Hetilap 141(21): 1121-1126, 2000

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research 52: 50-57, 2016

Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. British Journal of Haematology 149(3): 322-333, 2010

Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review. Zhongguo Shi Yan Xue Ye Xue Za Zhi 20(4): 1020-1024, 2013

Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24(2): 510-514, 2016

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93(11): 1712-1717, 2008

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer 121(6): 876-882, 2015

Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Current Opinion in Hematology 20(2): 137-143, 2013

Recent advances of studies on the therapy-related myelodysplastic syndromes/acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 22(6): 1757-1760, 2015